Olaratumab
13940
Phase 1 mab completed
Quick answer
Olaratumab for Malignancy is a Phase 1 program (mab) at Eli Lilly and Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly and Company
- Indication
- Malignancy
- Phase
- Phase 1
- Modality
- mab
- Status
- completed